Investor Centre

Clinical stage drug developer Pharmaxis Ltd (ASX: PXS) is pleased to announce the appointment of healthcare investment professional Hashan De Silva to the Board as a non-executive director.

Mr De Silva is an experienced life sciences investment professional. He worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research. Prior to moving into life science investment Mr De Silva worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.

Mr De Silva was educated at the University of New South Wales (Bachelor’s Degree in Medicine and Master’s Degree in Finance) and is a Chartered Financial Analyst.

Pharmaxis Chairman Malcolm McComas said, “We welcome Hashan to the Pharmaxis Board. He has been an enthusiastic supporter of the Company throughout his healthcare banking career including more recently as head of healthcare research at Karst Peak Capital where he conducted extensive diligence on our science which underpinned three separate investments in Pharmaxis. Hashan’s knowledge of the Australian and international healthcare capital markets brings relevant insight and experience to the Pharmaxis board.”

Mr De Silva said, “Pharmaxis has built a very impressive drug discovery and development capability unique from other ASX listed pharmaceutical companies. The clinical stage assets have generated exciting early data in diseases with high unmet need. I look forward to contributing to the commercialisation of these assets to create value for shareholders and deliver much needed new treatment options to patients.”